Frozen card revision. This is the recorded reading, not an automatically refreshed view. Current card ↗

Commercialization · TOPIC v3

Can Shield Bring More People into Colorectal Cancer Screening?

Can an easier blood draw bring in unscreened people and lead to completed diagnostic follow-up?

Read article → Can Shield Bring More People into Colorectal Cancer Screening?

2026-09-07 11:00:45.083 UTC · Last recorded update

CURRENT READING

Testing and revenue have grown. Track previously unscreened participants, diagnostic follow-up and assay improvements separately.

Recorded editorial state, not a maturity score

ApprovalRecorded
Use reportedRecorded
Coverage expansionScheduled
Incremental effectUnverified

Additional source checked · v2 → 3

Updated the related analysis after further source checks. This is not a newly announced trial or experiment.

Permanent link to this revision ↗

01 / WHAT WE TRACK

Can an easier blood draw bring in unscreened people and lead to completed diagnostic follow-up?

02 / EVIDENCE & TECHNOLOGY

cfDNA / blood-based colorectal cancer screening

Evidence: NEJM原著 ↗FDA審査資料 ↗FDA製品情報 ↗NCIの大腸がん検診解説 ↗中央病院の案内 ↗国立病院機構の任意検診案内 ↗国立がん研究センターのガイドライン ↗Guardant Health ↗

03 / EDITORIAL READING

Track testing revenue separately from screening value. Recruiting more participants through a blood draw is only part of the pathway; follow-up colonoscopy also matters.

04 / WHAT REMAINS UNKNOWN

Carelon coverage is scheduled for November 15. It cannot explain prior volume growth.

05 / NEXT CHECK

Who is newly screened, colonoscopy completion, testing costs and lesion-specific sensitivity.

Shield test volume~4.1×year over year

tests / quarter (company-reported, approximate)

2025 Q216,000

2026 Q266,000

Two same-quarter observations a year apart; the path between them is unknown. This does not measure the effect of the September Carelon announcement. Ratio calculated from rounded disclosures.

Sources: Guardant Health ↗

A hypothesis to keep honest

HYPOTHESIS · NOT YET TESTED

If blood testing reaches people who decline stool tests or colonoscopy, it could expand screening rather than merely substitute for existing tests.

What would change our view: Reconsider incremental value if use mainly replaces existing screening or positive results fail to lead to diagnostic follow-up.

A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.

Linked people & organizations

Open an entity to find its cards

COMPANYGuardant Health ↗

Provider of Shield and Guardant360 CDx; distinct products and uses.

Evidence: Guardant Health ↗FDA ↗

COMPANYCarelon Health Services ↗

Named in coverage announcement; policy text not independently checked.

Evidence: Guardant Health ↗

Latest card updates

Latest 5 · editorial record dates

v3 · 2026-09-07 11:00:45.083 UTCAdditional source checked
Updated the related analysis after further source checks. This is not a newly announced trial or experiment.
Reading at the time: Testing and revenue have grown. Track previously unscreened participants, diagnostic follow-up and assay improvements separately.

Earlier updates (0)

Earlier entries will appear here once more than five reader-facing revisions have accumulated.

Source-event timeline (different from editorial revisions)

2024-07-26Recorded event
FDA approval date, distinct from the issuer announcement.
Sources: FDA ↗
2026-07-30Recorded event
Q2 2026 test volumes disclosed by the company.
Sources: Guardant Health ↗
2026-09-01Recorded event
Carelon coverage announced by the company.
Sources: Guardant Health ↗
2026-11-15Scheduled
Announced effective date; implementation not yet confirmed.
Sources: Guardant Health ↗

Historical events were assembled through source research. They do not imply the magazine tracked them at the time.

Background readings

Commercialization